State Street Corp Increases Position in Illumina, Inc. (NASDAQ:ILMN)

State Street Corp grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 0.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,607,824 shares of the life sciences company's stock after buying an additional 10,680 shares during the quarter. State Street Corp owned 3.54% of Illumina worth $731,316,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ILMN. Bank of New York Mellon Corp increased its holdings in Illumina by 7.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company's stock worth $317,267,000 after purchasing an additional 204,043 shares during the period. Primecap Management Co. CA increased its holdings in Illumina by 3.6% during the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company's stock worth $328,158,000 after purchasing an additional 87,599 shares during the period. Janus Henderson Group PLC increased its holdings in Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock worth $282,735,000 after purchasing an additional 625,245 shares during the period. Millennium Management LLC increased its holdings in Illumina by 305.0% during the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company's stock worth $155,067,000 after purchasing an additional 1,118,747 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Illumina by 4.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company's stock worth $164,334,000 after purchasing an additional 54,319 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Stock Performance

Shares of ILMN stock traded up $6.44 on Monday, hitting $147.53. The company had a trading volume of 2,119,824 shares, compared to its average volume of 2,015,587. The firm has a market cap of $23.40 billion, a P/E ratio of -14.32 and a beta of 1.11. The company has a 50-day moving average price of $143.12 and a 200-day moving average price of $127.16. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a twelve month low of $100.08 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company's revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.33 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on ILMN shares. StockNews.com initiated coverage on Illumina in a report on Thursday, August 29th. They set a "buy" rating on the stock. HSBC upgraded Illumina from a "hold" rating to a "buy" rating and set a $180.00 price target on the stock in a report on Thursday, October 17th. Citigroup lifted their price target on Illumina from $155.00 to $190.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. Stephens lifted their price target on Illumina from $170.00 to $184.00 and gave the company an "overweight" rating in a report on Tuesday, November 12th. Finally, Hsbc Global Res upgraded Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price target on the stock in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.